GLUE - NASDAQ
Monte Rosa Therapeutics, Inc.
$17.59
-0.85%Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotMonte Rosa Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Monte Rosa Therapeutics, Inc. Income Statement
GLUE • NASDAQ
| Monte Rosa Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
123.7M | 75.6M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||
(8.4M) | (8.1M) | (6.2M) | (0.0) | (0.0) | (537K) | (72K) | |
115.3M | 67.5M | -6.2M | 0.0 | 0.0 | -537K | -72K | |
OPERATING INCOME | |||||||
(169.5M) | (148.6M) | (137.1M) | (112.4M) | (72.9M) | (27.5M) | (8M) | |
(36.4M) | (35.2M) | (32M) | (27.3M) | (15.7M) | (4M) | (644K) | |
(141.5M) | (121.6M) | (105.1M) | (85.1M) | (57.2M) | (23.5M) | (7.4M) | |
-54.2M | -81.1M | -143.3M | -112.4M | -72.9M | -28M | -8M | |
PRE-TAX INCOME | |||||||
(0.0) | (0.0) | (0.0) | (3.8M) | (0.0) | (0.0) | (1K) | |
12.9M | 10.6M | 9.3M | 0.0 | 46K | 9K | -988.0 | |
-8.4M | -8.1M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
14.5M | 11M | 8.3M | 3.9M | -1.1M | -7.9M | 254K | |
-39.7M | -70.1M | -135M | -108.5M | -74M | -35.9M | -7.7M | |
NET INCOME | |||||||
-1.1M | (2.6M) | (338K) | (0.0) | (0.0) | (0.0) | (0.0) | |
-38.6M | -72.7M | -135.4M | -108.5M | -74M | -35.9M | -8M |
SEC Filings
GLUE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 16, 2025 | December 16, 2025 | 2025 |
Related Guides
Continue your GLUE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.